{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-014281","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.645974+00:00","generated_at":"2026-06-11T22:26:31.695186+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NeuroBo Q2 net loss narrows to $0.7M; DA-1241 Phase 2a dosing expected Sept 2023","bullets":["Net loss of $0.7M ($0.02/share) in Q2 2023 vs $3.3M in Q2 2022; cash $28.7M sufficient into 2024.","First patient dosing in Phase 2a trial of DA-1241 for NASH expected September 2023.","Signed term sheet with MThera to out-license NB-01 for painful diabetic neuropathy worldwide except Korea.","Preclinical data for DA-1726 shows superior weight loss vs semaglutide and tirzepatide; IND submission expected H2 2023.","R&D expenses increased to $2.4M from $1.0M YoY, driven by DA-1241 preparation."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-014281","json":"https://secwatch.observer/filing/0001558370-23-014281.json","markdown":"https://secwatch.observer/filing/0001558370-23-014281.md","text":"https://secwatch.observer/filing/0001558370-23-014281.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837023014281/0001558370-23-014281-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837023014281/nrbo-20230809x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T22:26:31.695186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"859ea10fae2db2e9e6201026822c67848f8da3c8","claim":"MetaVia Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"NeuroBo Pharmaceuticals, Inc. (the “Company” ) issued a press release announcing its financial results for the second quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638287/000155837023014281/0001558370-23-014281-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}